[go: up one dir, main page]

PE20040516A1 - Derivados de 1,2-azol - Google Patents

Derivados de 1,2-azol

Info

Publication number
PE20040516A1
PE20040516A1 PE2003000503A PE2003000503A PE20040516A1 PE 20040516 A1 PE20040516 A1 PE 20040516A1 PE 2003000503 A PE2003000503 A PE 2003000503A PE 2003000503 A PE2003000503 A PE 2003000503A PE 20040516 A1 PE20040516 A1 PE 20040516A1
Authority
PE
Peru
Prior art keywords
pirazo
etoxy
lil
substitutes
trifluoromethyl
Prior art date
Application number
PE2003000503A
Other languages
English (en)
Inventor
Kohji Fukatsu
Ryoma Hara
Hiroyuki Odaka
Tsuyoshi Maekawa
Hideya Mizufune
Hiroyuki Kimura
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PE20040516A1 publication Critical patent/PE20040516A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES UN ANILLO CON 1 A 3 TRES SUSTITUYENTES; B ES UN ANILLO 1,2- AZOL CON 1 A 3 SUSTITUYENTES; Xa, Xb Y Xc SON CADA UNO UN ENLACE, -O-, -S-, -SO-, -CS-, ENTRE OTROS; Ya ES RESIDUO DE HIDROCARBURO ALIFATICO DIVALENTE CON 1 A 20 ATOMOS DE CARBONO; Yb E Yc SON CADA UNO UN ENLACE O RESIDUO DE HIDROCARBURO ALIFATICO DIVALENTE CON 1 A 20 ATOMOS DE CARBONO; C ES ANILLO AROMATICO MONOCICLICO CON 1 A 3 SUSTITUYENTES; R ES -OR4, -NR5R6; R4 ES H, HIDROCARBURO; R5 Y R6 SON CADA UNO H, HIDROCARBURO Y GRUPO HETEROCICLICO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 3-[1-FENIL-3-(4-{3-[4-(TRIFLUOROMETIL)FENIL]-5-ISOXAZOLIL}BUTOXI-1H-PIRAZO-5-LIL]PROPIONICO; ACIDO 2-[3-(3-{3-ETOXI-1-[5-(TRIFLUOROMETIL)-2-PIRIDIL]-1H-PIRAZO-4-LIL}PROPOXI)FENOXI]-2-METILPROPIONICO Y ACIDO 3-[2-ETOXI-4-(3-{3-ETOXI-1-[5-(TRIFLUOROMETIL)-2-PIRIDIL]-1H-PIRAZO-4-LIL}PROPOXI)FENIL]PROPIONICO. SE REFIERE TAMBIEN A UN METODO DE PRODUCCION DE DICHOS COMPUESTOS QUE SON UTILES PARA PROFILAXIS O TRATAMIENTO DE DIABETES, HIPERLIPIDEMIA, ARTERIOESCLEROSIS, TOLERANCIA PERJUDICIAL A LA GLUCOSA Y SIMILARES
PE2003000503A 2002-05-24 2003-05-23 Derivados de 1,2-azol PE20040516A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002151405 2002-05-24
JP2002287161 2002-09-30
JP2003016748 2003-01-24

Publications (1)

Publication Number Publication Date
PE20040516A1 true PE20040516A1 (es) 2004-10-01

Family

ID=29587460

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000503A PE20040516A1 (es) 2002-05-24 2003-05-23 Derivados de 1,2-azol

Country Status (8)

Country Link
US (1) US20060148858A1 (es)
EP (1) EP1513817A1 (es)
AR (1) AR040043A1 (es)
AU (1) AU2003241173A1 (es)
CA (1) CA2487315A1 (es)
PE (1) PE20040516A1 (es)
TW (1) TW200407309A (es)
WO (1) WO2003099793A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
EP1559422B1 (en) * 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004063166A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heterocyclic ppar modulators
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315569A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
US20070032537A1 (en) * 2003-06-13 2007-02-08 Arena Pharmaceuticals, Inc. 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases
WO2005019184A1 (en) 2003-08-20 2005-03-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
DE602004006279T2 (de) * 2003-08-20 2007-12-27 Eli Lilly And Co., Indianapolis Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4-rezeptor-(mc4-)agonistschen peptids
CA2547430A1 (en) 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited Receptor function regulating agent
WO2005063729A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
EA011010B1 (ru) 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
JP4599395B2 (ja) * 2004-03-09 2010-12-15 エフ．ホフマン−ラ ロシュ アーゲー Ｐｐａｒ活性化剤としてのピラゾリルインドリル誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005099759A1 (ja) * 2004-04-16 2005-10-27 Institute Of Medicinal Molecular Design. Inc. 動脈硬化症の予防及び／又は治療のための医薬
JP2007284350A (ja) * 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US20080045580A1 (en) * 2004-10-11 2008-02-21 Dr Reddy's Laboratories Limited Novel Isoxazole Compounds Having Ppar Agonist Activity
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
WO2006126692A1 (ja) 2005-05-23 2006-11-30 Sagami Chemical Research Center ピラゾール-1-カルボン酸エルテル誘導体、その製造方法及びピラゾール誘導体類の製造方法
JPWO2006126514A1 (ja) 2005-05-27 2008-12-25 塩野義製薬株式会社 イソキサゾール骨格を有するアリール酢酸誘導体
RU2008108221A (ru) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
NZ572268A (en) 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
US9162953B2 (en) * 2006-07-05 2015-10-20 Centre Nationale De Recherche Scientifique Iron-copper co-catalyzed process for carbon-carbon or carbon-heteroatom bonding
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
JPWO2008093639A1 (ja) * 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
JP2010517935A (ja) * 2007-02-09 2010-05-27 武田薬品工業株式会社 Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
AU2008311355B2 (en) 2007-10-10 2012-01-19 Amgen Inc. Substituted biphenyl GPR40 modulators
NZ585308A (en) 2007-12-04 2012-03-30 Hoffmann La Roche Isoxazolo-pyridine derivatives
BRPI0912245A2 (pt) 2008-03-05 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
PT2277874T (pt) 2008-04-15 2018-08-10 Nippon Chemiphar Co Ativador para recetor ativado por proliferador de peroxissoma
ES2450567T3 (es) 2008-10-15 2014-03-25 Amgen, Inc Moduladores de GPR40 espirocíclicos
AR073949A1 (es) * 2008-10-21 2010-12-15 Metabolex Inc Agonistas del receptor aril-gpr120 y usos de los mismos
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
EA201690035A1 (ru) 2011-02-25 2016-05-31 Мерк Шарп Энд Домэ Корп. Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
EP2897953B8 (en) * 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
JP6322203B2 (ja) 2012-11-16 2018-05-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ジヒドロピラゾールｇｐｒ４０モジュレーター
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
PT2988743T (pt) 2013-03-15 2021-03-03 Epigen Biosciences Inc Compostos heterocíclicos úteis no tratamento da doença
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
IL280785B2 (en) 2014-03-07 2024-09-01 Biocryst Pharm Inc Human plasma kallikrein inhibitors
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110143910B (zh) * 2019-06-03 2022-04-05 华侨大学 一种多取代吡咯烷酮衍生物的制备方法
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
DE3836581A1 (de) * 1988-10-27 1990-05-03 Basf Ag Heterocyclisch substituierte (alpha)-aryl-acrylsaeuremethylester und ihre verwendung
US5166216A (en) * 1988-10-27 1992-11-24 Basf Aktiengesellschaft Methyl α-arylacrylates substituted by a heterocyclic radical and their use
DE69018592T2 (de) * 1989-12-13 1995-10-05 Mitsubishi Chem Corp Pyrazolylacrylsäure-Derivate, verwendbar als systemische Fungiziden in Pflanzen- und Materialschutz.
US4956376A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Tetrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
CA2036192A1 (en) * 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US5236938A (en) * 1991-04-30 1993-08-17 Rhone-Poulenc Inc. Pesticidal 1-aryl-5-(substituted alkylideneimino)pyrazoles
DE4116090A1 (de) * 1991-05-17 1992-11-19 Basf Ag (alpha)-phenylacrylsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen und schadpilzen
DE4117371A1 (de) * 1991-05-28 1992-12-03 Basf Ag Antimykotische mittel, die phenylessigsaeurederivate enthalten
DE4124989A1 (de) * 1991-07-27 1993-02-04 Basf Ag (beta)-substituierte zimtsaeurederivate
DE4126994A1 (de) * 1991-08-16 1993-02-18 Basf Ag (alpha)-arylacrylsaeurederivate, ihre herstellung und verwendung zur bekaempfung von schaedlingen und pilzen
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
EP0581095A2 (de) * 1992-07-24 1994-02-02 BASF Aktiengesellschaft Substituierte Acrylsäureester und diese enthaltende Pflanzenschutzmittel
DE4305502A1 (de) * 1993-02-23 1994-08-25 Basf Ag Ortho-substituierte 2-Methoxyiminophenylessigsäuremethylamide
DE4338104A1 (de) * 1993-11-08 1995-05-11 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
KR970006238B1 (en) * 1994-03-15 1997-04-25 Korea Res Inst Chem Tech Propenoic ester derivatives having 4-hydroxy pyrazole group
IL113414A (en) * 1994-05-03 2000-08-13 Basf Ag Substituted methyl alpha-phenylbutenoates their preparation and use for combating harmful fungi and animal pests
ES2137411T3 (es) * 1994-07-06 1999-12-16 Basf Ag Derivados de pirazolilo, su obtencion y su empleo como agentes pesticidas.
ATE202562T1 (de) * 1995-05-09 2001-07-15 Basf Ag (het)aryloxy-, -thio-, aminocrotonate, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von tierischen schädlin gen und schadpilzen
DE19519041A1 (de) * 1995-05-24 1996-11-28 Basf Ag Azolyloxybenzyl-alkoxyacrylsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2740135B1 (fr) * 1995-10-20 1997-12-19 Roussel Uclaf Nouveaux derives de pyrazoles acides, leur procede de preparation, leur application a titre de medicaments, leur nouvelle utilisation et les compositions pharmaceutiques les renfermant
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CO5060426A1 (es) * 1997-03-10 2001-07-30 Rhone Poulenc Agrochimie 1-aril-3-imidiopirazoles plaguicidas
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
PL200408B1 (pl) * 1997-09-05 2009-01-30 Basf Ag Sposób wytwarzania (hetero)aromatycznych hydroksyloamin i sposób wytwarzania N-acylowanych (hetero)aromatycznych hydroksyloamin
US6080839A (en) * 1998-06-25 2000-06-27 Wallac Oy Labeling reactants and their use
PT1177176E (pt) * 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
NZ519238A (en) * 1999-11-10 2003-11-28 Takeda Chemical Industries Ltd 5-membered N-heterocyclic compounds with hypolglycemic and hypolipidemic activity
ATE381542T1 (de) * 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen

Also Published As

Publication number Publication date
AU2003241173A1 (en) 2003-12-12
AU2003241173A8 (en) 2003-12-12
US20060148858A1 (en) 2006-07-06
AR040043A1 (es) 2005-03-09
EP1513817A1 (en) 2005-03-16
CA2487315A1 (en) 2003-12-04
TW200407309A (en) 2004-05-16
WO2003099793A1 (en) 2003-12-04
WO2003099793A9 (en) 2005-02-10
WO2003099793A8 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
PE20040516A1 (es) Derivados de 1,2-azol
PE20040577A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion y medicamentos que las comprenden
PE20001562A1 (es) Derivados de benzamida como inhibidores de la produccion hepatica de la apo proteina b-100
PE20000947A1 (es) ACTIVADORES DE hPPARþ Y hPPARO
PE20060825A1 (es) Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE57799A1 (es) Derivados de acidos arilsulfonilaminohidroxamicos
PE20050147A1 (es) Derivados de pirimidina, piridina y tiazol como inhibidores de fosfatidilinositol 3-quinasa
PE20080259A1 (es) Compuestos y metodos para modular fxr
PE20051146A1 (es) Compuestos heterociclicos anticitocina
PE20050444A1 (es) Compuestos de piridina como inhibidores de la peptidasa
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
PE20060417A1 (es) Indazoles como moduladores de lxrs
AU5257401A (en) Novel bicyclic compounds
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
TW200914429A (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
JP2008505874A5 (es)
CO5251452A1 (es) Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar
PE20051159A1 (es) Derivados de heteroarilaminopirazol como estimulantes de la produccion de insulina
PE20020753A1 (es) Heteroaromaticos fusionados como activadores de la glucoquinasa
FI884350A0 (fi) Som antagonister nyttiga nya benzimidazolin-2-oxo-1-karboxylsyraderivat av 5-ht reseptor.
DE60129712D1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20050079A1 (es) Derivados de pirrolidona como inhibidores de maob
PE20091930A1 (es) Compuestos de pirazol, procesos para su produccion y herbicidas que los contienen
NO20080323L (no) Forbindelser og deres salter som er spesifikke overfor PPAR-reseptorer og EGF-reseptorer og deres anvendlse innen medisinen

Legal Events

Date Code Title Description
FC Refusal